I currently work as a Research Assistant in the Departments of Medical Genetics and Translational Medicine at Bursa Uludağ University, Bursa, Türkiye. My primary research focuses on identifying epigenetic biomarkers and elucidating their interactions in contributing to cancer risk.
I graduated with honours from the Department of Biology at Hacettepe University, Ankara, Turkey. During my undergraduate studies, I had the opportunity to enhance my research skills through the Erasmus Internship Program at the Centre for Integrative Biology in Trento, Italy. I pursued my Master of Science degree in the Department of Molecular Biology and Genetics at Istanbul University, where my research centred on identifying and validating novel ovarian cancer-specific microRNAs in serum using high-throughput techniques.
For my PhD thesis in the Department of Translational Medicine at Bursa Uludağ University, I investigated circulating tumor cells and metastasis-related circulating microRNA expression pro
EDUCATION
Ph.D. in Translational Medicine
Bursa Uludağ University, Bursa, Türkiye (2020 – 2024)
M.Sc. in Molecular Biology and Genetics
Istanbul University, Istanbul, Türkiye (2015 – 2018)
B.Sc. in Biology
Hacettepe University, Ankara, Türkiye (2010 – 2015)
RESEARCH, TEACHING, or OTHER INTERESTS
Health Informatics, Cancer Research, Genetics, Molecular Medicine
Integrative Bioinformatic Approach for microRNA Interactome Networks in Human Papillomavirus-16 Infection Berkcan Doğan Eurasian Journal of Medicine, 2025 Objective: High-risk human papillomavirus (HPV), particularly HPV-16, is a major driver of carcinogenesis. Despite advances in understanding HPV-mediated oncogenesis, the role of microRNA (miRNA) interactome networks in HPV-16-driven tumorigenesis remains unclear. Using an integrative bioinformatic approach, this study identified key miRNAs, target genes, and transcription factors (TFs) involved in HPV-16–associated cancers.Methods: Human papillomavirus-16–associated miRNAs were retrieved from viRBase. microRNAs and their interactors were analyzed using The Cancer Genome Atlas and Genotype-tissue Expression datasets to investigate the expression patterns and potential roles in carcinogenesis. microRNA–messenger RNA (mRNA) interactions, TFs enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and GO terms analyses uncovered molecular networks disrupted by HPV-16. Receiver operating characteristic curve (ROC) and Kaplan-Meier analyses assessed the clinical significance of dysregulated miRNAs.Results: Eight miRNAs (hsa-miR-16-5p, hsa-miR-24-3p, hsa-miR-34a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-203a-3p, hsa-miR-205-5p, and hsa-miR-331-3p) were significantly dysregulated in HPV-16 infection and enriched in key KEGG pathways, highlighting involvement in cellular processes and regulatory mechanisms. Among these, hsa-miR-100-5p, hsa-miR-125b-5p, and hsa-miR-331-3p were the most significant in HPV-16-driven cancer types, with hsa-miR-125b-5p emerging as a key prognostic regulator. MAP3K13 and NR1H4 were identified as critical gene and TF candidates in HPV-16 carcinogenesis.Conclusion: This study provides novel insights into miRNA interactome networks in HPV-16–driven carcinogenesis, identifying biomarkers and therapeutic targets. Integrating translational bioinformatic insights with experimental validation paves the way for developing targeted diagnostic and therapeutic strategies and unravelling complex host–virus interactions, ultimately enhancing the management of HPV-associated cancers.Cite this article as: Doğan B. Integrative bioinformatic approach for miRNA interactome networks in HPV16 infection. Eurasian J Med. 2025, 57(3), 0817, doi: 10.5152/eurasianjmed.2025.25817.
The Potential Role of Egg-Derived Xeno-miRs in Chemotherapy Response: An In Silico Approach Berkcan Doğan Food Science and Nutrition, 2025 Exogenous microRNAs (Xeno‐miRs), primarily derived from dietary sources, are detectable in host biofluids and influence gene expression through cross‐kingdom regulation. Despite growing interest, their impact on human diseases, especially cancer, remains controversial and requires further investigation. However, the specific implications of diet‐derived Xeno‐miRs in chemotherapy response remain largely unexplored. This study assesses the potential functions and possible implications of egg‐derived miRNAs in chemotherapy response with an in silico approach. This study presents the first evaluation of the contribution of diet‐derived miRNAs in modulating chemotherapy outcomes. Egg‐derived miRNAs were retrieved from the Dietary MicroRNA Database, and their human homologs were identified. Target genes and transcription factors were predicted using mirDIP and TransmiR databases, respectively. Pathway enrichment analysis was conducted with DIANA‐miRPath. Expression patterns of Xeno‐miRs were analyzed using the CancerMIRNome database, and differentially expressed target genes were identified using TCGA and GTEx data via GEPIA2. The chemotherapy response of Xeno‐miRs was assessed using ncRNADrug. Fifty‐five egg‐derived Xeno‐miRs were initially retrieved, among which 17 human homologs were further analyzed. Notably, the downregulation of hsa‐miR‐30a‐5p and hsa‐miR‐146a‐5p was associated with increased sensitivity to fluorouracil and oxaliplatin, whereas the overexpression of hsa‐miR‐22‐3p and hsa‐miR‐200a‐3p was linked to resistance against testosterone and bortezomib ( p < 0.0001, logFC ≥ 2 or ≤ −2). This study provides in silico evidence for the role of dietary miRNAs in chemotherapy response, paving the way for their translational application in nutrition‐based cancer management strategies. Further experimental studies are required to quantify their bioavailability post‐digestion and to characterize their cellular uptake mechanisms.
THE DEVELOPMENT OF A FUZZY LOGIC SYSTEM USING MATLAB FOR EARLY DETECTION OF HEREDITARY CANCER IN BRCA1/2 NEGATIVE CASES L. Aliyeva, N. Senturk, G.P. Volkan, Babiker S.M. Ali, O.S. Sag, et al. Balkan Journal of Medical Genetics, 2025 The purpose of our study is to expedite cancer diagnosis through the development of software for rapid detection of hereditary breast cancer (BC) with negative BRCA1/2 on MATLAB, utilizing a fuzzy logic system with several variants of genes associated with BC. This system serves as a clinical decision-support tool, assisting in early classification and interpretation of genetic variants by combining clinical and genetic data. Clinical data were obtained from Erciyes University Faculty of Medicine Department of Medical Genetics and Uludağ University Faculty of Medicine Department of Medical Genetics. 488 individuals were studied. Only 90 of them were relevant to our investigation since their BRCA1/2 genes did not exhibit notable genetic mutations. We examined 16 distinct breast cancer risk factors and focused on mutations related to 18 hereditary BC genes. The collected data were integrated into the developed system, and various membership functions were given varying degrees of possibility, ranging from 0 to 1, depending on their participation in input clusters. After the system was trained on 90 cases and validated on six independent patients, its accuracy was assessed, yielding reliable results. Following the training phase, outcomes revealed the presence of two pathogenic variants at 0.92 (92%), two benign variants at 0.25 (25%), and two variants of unknown significance at 0.5 (50%). Given the high incidence of breast cancer, early prediction is paramount. Despite the emergence of fuzzy logic systems in medical applications, limited research akin to our study exists. The establishment of this artificial intelligence software holds promise for advancing the early detection of BC in future clinical applications.
Candidate Biomarkers Associated With Circulating Tumor Cell Status in Metastatic Colorectal Cancer Berkcan Doğan, Dilek Pirim, Özgen Işık, Türkkan Evrensel Journal of Clinical Laboratory Analysis, 2025 BackgroundColorectal cancer (CRC) ranks as the third most prevalent cancer worldwide. Recent studies suggest the promising potential of microRNAs (miRNA) in predicting the status of circulating tumor cells (CTC), and their combined analyses could pave the way for significant advancements in assessing the risk of metastatic cancer. Here, we investigate the circulating miRNA signatures associated with CTC status in metastatic CRC (mCRC).MethodsThe CTC status of mCRC patients was assessed using AdnaTest ColonCancer technology, which detects tumor cells using an immunomagnetic approach and characterizes them based on colon‐specific surface markers. The miRNA profiles were analyzed using the Agilent miRNA microarray in 8 CTC‐positive, 8 CTC‐negative, and eight healthy individuals. The functional implications of dysregulated miRNAs and their interactions with target mRNAs, TFs, and lncRNAs were determined through a comprehensive in silico analysis. Candidate miRNAs that were differentially expressed in CTC‐positive and CTC‐negative groups, which have prior evidence for their role in CRC biology, were validated using qPCR.ResultsWe identified two groups of dysregulated miRNAs associated with CTC status and multiple candidate biomarkers in suggested miRNA regulatory networks. Three miRNAs (hsa‐miR‐199a‐5p, hsa‐miR‐326, hsa‐miR‐500b‐5p), which were downregulated in the CTC‐positive group compared to the CTC‐negative group, were confirmed by qPCR and prioritized as candidate predictors of CTC status in mCRC.ConclusionOur findings suggest biomarker candidates that can be used to predict CTC status in individuals with mCRC. This might also provide new insights into new translational medicine applications in the management of mCRC through miRNA‐based CRC‐associated CTC detection.
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey Ibrahim Boga, Sebnem Ozemri Sag, Nilgun Duman, Sevda Yesim Ozdemir, Mahmut Cerkez Ergoren, Kubilay Dalci, Cem Mujde, Cem Kaan Parsak, Cagla Rencuzogullari, Ozge Sonmezler, Orcun Yalav, Adem Alemdar, Lamiya Aliyeva, Ozlem Bozkurt, Sibel Cetintas, Erdem Cubukcu, Adem Deligonul, Berkcan Dogan, Cemre Ornek Erguzeloglu, Turkkan Evrensel, Sehsuvar Gokgoz, Kazim Senol, Sahsine Tolunay, Esra Akyurek, Neslihan Basgoz, Nuriye Gökçe, Bilge Dundar, Figen Ozturk, Duygu Taskin, Mercan Demirtas, Murat Cag, Omer Diker, Polat Olgun, Sevcan Tug Bozdogan, Munis Dundar, Atil Bisgin, Sehime Gulsun Temel European Journal of Breast Health, 2023 Objective: , which are strongly associated with BC, are included in these criteria. The aim of this study was to compare BC index cases with non-BC individuals in terms of genotype and diagnostic features to investigate the genotype/demographic information association. Materials and Methods: genes was performed in 2475 individuals between 2013-2022 from collaborative centers across Turkey, of whom 1444 with BC were designated as index cases. Results: (p<0.05). Meta-analyses were performed to compare these results with other studies of Mediterranean-region populations. Conclusion: variants, as expected, and these results were consistent with the data of Mediterranean-region populations. However, the present study, because of the large sample size, revealed more robust findings than previous studies. These findings may be helpful in facilitating the clinical management of BC for both familial and non-familial cases.
Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer Ece Gumusoglu‑Acar, Tuba Gunel, Mohammad Hosseini, Berkcan Dogan, Efnan Tekarslan, Berk Gurdamar, Nazife Cevik, Ugur Sezerman, Samet Topuz, Kilic Aydinli Oncology Letters, 2023 Epithelial ovarian cancer (EOC) is the type of OC with the highest mortality rate. Due to the asymptomatic nature of the disease and few available diagnostic tests, it is mostly diagnosed at the advanced stage. Therefore, the present study aimed to discover predictive and/or early diagnostic novel circulating microRNAs (miRNAs or miRs) for EOC. Firstly, microarray analysis of miRNA expression levels was performed on 32 samples of female individuals: Eight plasma samples from patients with pathologically confirmed EOC (mean age, 45 (30-54) years), eight plasma samples from matched healthy individuals (HIs) (mean age, 44 (30-65) years), eight EOC tissue samples (mean age, 45 (30-54) years) and eight benign ovarian (mean age, 35 (17-70) years) neoplastic tissue samples A total of 31 significantly dysregulated miRNAs in serum and three miRNAs in tissue were identified by microarray. The results were validated using reverse transcription-quantitative PCR on samples from 10 patients with pathologically confirmed EOC (mean age, 47(30-54) years), 10 matched His (mean age, 40(26-65) years], 10 EOC tissue samples (mean age, 47(30-54) years) and 10 benign ovarian neoplastic tissue samples (mean age, 40(17-70) years). The 'Kyoto Encyclopedia of Genes and Genomes' (KEGG) database was used for target gene and pathway analysis. A total of three miRNAs from EOC serum (hsa-miR-1909-5p, hsa-miR-885-5p and hsa-let-7d-3p) and one microRNA from tissue samples (hsa-miR-200c-3p) were validated as significant to distinguish patients with EOC from HIs. KEGG pathway enrichment analysis showed seven significant pathways, which included 'prion diseases', 'proteoglycans in cancer', 'oxytocin signaling pathway', 'hippo signaling pathway', 'adrenergic signaling in cardiomyocytes', 'oocyte meiosis' and 'thyroid hormone signaling pathway', in which the validated miRNAs served a role. This supports the hypothesis that four validated miRNAs, have the potential to be a biomarker of EOC diagnosis and target for treatment.
Different perspectives on translational genomics in personalized medicine Berkcan Doğan, Hale Göksever Çelik, Reyhan Diz Küçükkaya, Ece Gümüşoğlu Acar, Tuba Günel Journal of the Turkish German Gynecology Association, 2022 Personalized medicine is a relatively new and interesting concept in the medical and healthcare industries. New approaches in current research have supported the search for biomarkers, based on the genomic, epigenomic and proteomic profile of individuals, using new technological tools. This perspective involves the potential to determine optimal medical interventions and provide the optimal benefit-risk balance for treatment, whilst it also takes a patient's personal situation into consideration. Translational genomics, a subfield of personalized medicine, is changing medical practice, by facilitating clinical or non-clinical screening tests, informing diagnoses and therapeutics, and routinely offering personalized health-risk assessments and personalized treatments. Further research into translational genomics will play a critical role in creating a new approach to cancer, pharmacogenomics, and women's health. Our current knowledge may be used to develop new solutions that can be used to minimize, improve, manage, and delay the symptoms of diseases in real-time and maintain a healthy lifestyle. In this review, we define and discuss the current status of translational genomics in some special areas including integration into research and health care.
Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey Atil Bisgin, Sebnem Ozemri Sag, Muhammet E. Dogan, Mahmut S. Yildirim, Aydeniz Aydin Gumus, Nejmiye Akkus, Ozgur Balasar, Ceren D. Durmaz, Recep Eroz, Sule Altiner, Adem Alemdar, Lamia Aliyeva, Ibrahim Boga, Fethi S. Cam, Berkcan Dogan, Onur Esbah, Abdullah Hanta, Cem Mujde, Cemre Ornek, Sinem Ozer, Cagla Rencuzogullari, Ozge Sonmezler, Sevcan Tug Bozdogan, Munis Dundar, Sehime G. Temel Breast, 2022 BRCA1/2 mutations play a significant role in cancer pathogenesis and predisposition particularly in breast, ovarian and prostate cancers. Thus, germline analysis of BRCA1 and BRCA2 is essential for clinical management strategies aiming at the identification of recurrent and novel mutations that could be used as a first screening approach. We analyzed germline variants of BRCA1/2 genes for 2168 individuals who had cancer diagnosis or high risk assessment due to BRCAs related cancers, referred to 10 health care centers distributed across 7 regions covering the Turkish landscape. Overall, 68 and 157 distinct mutations were identified in BRCA1 and BRCA2, respectively. Twenty-two novel variants were reported from both genes while BRCA2 showed higher mutational heterogeneity. We herein report the collective data as BRCA Turkish consortium that confirm the molecular heterogeneity in BRCAs among Turkish population, and also as the first study presenting the both geographical, demographical and gene based landscape of all recurrent and novel mutations which some might be a founder effect in comparison to global databases. This wider perspective leads to the most accurate variant interpretations which pave the way for the more precise and efficient management affecting the clinical and molecular aspects.
The evaluation of the HSP70 and TCP1 status of circulating tumor cells derived from metastatic colorectal cancer patients D Pirim, B Dogan, FA Bağcı, Ö Işık, T Evrensel Journal of Experimental and Clinical Medicine 42 (4), 417-422 , 2025 2025
Integrative Bioinformatic Approach for microRNA Interactome Networks in Human Papillomavirus-16 Infection B Doğan The Eurasian Journal of Medicine 57 (3), e25817 , 2025 2025
The Potential Role of Egg‐Derived Xeno‐miRs in Chemotherapy Response: An In Silico Approach B Doğan Food Science & Nutrition 13 (6), e70332 , 2025 2025 Citations: 1
Candidate biomarkers associated with circulating tumor cell status in metastatic colorectal cancer B Doğan, D Pirim, Ö Işık, T Evrensel Journal of clinical laboratory analysis 39 (7), e70013 , 2025 2025 Citations: 4
The Development of a Fuzzy Logic System Using MATLAB for Early Detection of Hereditary Cancer in BRCA1/2 Negative Cases N Senturk, GP Volkan, SMB Ali, B Dogan, L Aliyeva, OS Sag, GS Temel, ... Balkan Journal of Medical Genetics 28 (1) , 2025 2025
Metastatik kolorektal kanserde dolaşımdaki tümör hücresi durumuyla ilişkili aday biyobelirteçlerin araştırılması B Doğan Bursa Uludağ Üniversitesi , 2024 2024
The Expression Analysis of Specific Genes in Ovarian Cancer E Gümüşoğlu-acar, B Doğan, MU Bilir, T Senturk-kirmizitas, S Topuz, ... Doğu Karadeniz Sağlık Bilimleri Dergisi 2 (Kongre Özel Sayısı), 136-143 , 2023 2023
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey European Journal of Breast Health 19 (3), 235-252 , 2023 2023 Citations: 7
Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer E Gumusoglu-Acar, T Gunel, MK Hosseini, B Dogan, EE Tekarslan, ... Oncology Letters 25 (4), 142 , 2023 2023 Citations: 16
Investigation of putative roles of smoking-associated salivary microbiome alterations on carcinogenesis by integrative in silico analysis B Doğan, B Ayar, D Pirim Computational Biology and Chemistry 102, 107805 , 2023 2023
Different perspectives on translational genomics in personalized medicine B Doğan, HG Çelik, RD Küçükkaya, EG Acar, T Günel Journal of the Turkish German Gynecological Association 23 (4), 314 , 2022 2022 Citations: 4
Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey A Bisgin, SO Sag, ME Dogan, MS Yildirim, AA Gumus, N Akkus, O Balasar, ... The Breast 65, 15-22 , 2022 2022 Citations: 9
Integrated bioinformatics analysis of validated and circulating miRNAs in ovarian cancer B Dogan, E Gumusoglu, E Ulgen, OU Sezerman, T Gunel Genomics & informatics 20 (2), e20 , 2022 2022 Citations: 11
Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium M Dundar, U Fahrioglu, SH Yildiz, B Bakir-Gungor, SG Temel, H Akin, ... Functional & integrative genomics 22 (3), 291-315 , 2022 2022 Citations: 20
Kök Hücreler B Doğan, D Pirim Nobel Yayınevi , 2022 2022
BRCA Variations Risk Assessment in Breast Cancers Using Different Artificial Intelligence Models N Senturk, G Tuncel, B Dogan, L Aliyeva, MS Dundar, S Ozemri Sag, ... Genes 12 (11), 1774 , 2021 2021 Citations: 12
In silico identification of putative roles of food-derived xeno-mirs on diet-associated cancer D Pirim, B Dogan Nutrition and cancer 72 (3), 481-488 , 2020 2020 Citations: 7
Klinik Araştırmalarda MiRNA Keşfi ve Güncel In Silico Yaklaşımlar B Doğan, D Pirim, B Ayar Güncel Tıbbi Biyoloji ve Genetik Çalışmaları, 1-20 , 2020 2020
Hsa-miR-584-5p as a novel candidate biomarker in Turkish men with severe coronary artery disease N Coban, D Pirim, AF Erkan, B Dogan, B Ekici Molecular Biology Reports , 2019 2019 Citations: 12
Regulation of HMGA2 and KRAS genes in epithelial ovarian cancer by miRNA hsa-let-7d-3p T Gunel, B Dogan, E Gumusoglu, MK Hosseini, S Topuz, K Aydinli Journal of cancer research and therapeutics 15 (6), 1321-1327 , 2019 2019 Citations: 24
MOST CITED SCHOLAR PUBLICATIONS
Regulation of HMGA2 and KRAS genes in epithelial ovarian cancer by miRNA hsa-let-7d-3p T Gunel, B Dogan, E Gumusoglu, MK Hosseini, S Topuz, K Aydinli Journal of cancer research and therapeutics 15 (6), 1321-1327 , 2019 2019 Citations: 24
Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer T Günel, E Gumusoglu, B Dogan, FB Ertem, MK Hosseini, N Cevik, ... Archives of gynecology and obstetrics 298 (6), 1173-1180 , 2018 2018 Citations: 24
Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium M Dundar, U Fahrioglu, SH Yildiz, B Bakir-Gungor, SG Temel, H Akin, ... Functional & integrative genomics 22 (3), 291-315 , 2022 2022 Citations: 20
Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer E Gumusoglu-Acar, T Gunel, MK Hosseini, B Dogan, EE Tekarslan, ... Oncology Letters 25 (4), 142 , 2023 2023 Citations: 16
BRCA Variations Risk Assessment in Breast Cancers Using Different Artificial Intelligence Models N Senturk, G Tuncel, B Dogan, L Aliyeva, MS Dundar, S Ozemri Sag, ... Genes 12 (11), 1774 , 2021 2021 Citations: 12
Hsa-miR-584-5p as a novel candidate biomarker in Turkish men with severe coronary artery disease N Coban, D Pirim, AF Erkan, B Dogan, B Ekici Molecular Biology Reports , 2019 2019 Citations: 12
Integrated bioinformatics analysis of validated and circulating miRNAs in ovarian cancer B Dogan, E Gumusoglu, E Ulgen, OU Sezerman, T Gunel Genomics & informatics 20 (2), e20 , 2022 2022 Citations: 11
Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey A Bisgin, SO Sag, ME Dogan, MS Yildirim, AA Gumus, N Akkus, O Balasar, ... The Breast 65, 15-22 , 2022 2022 Citations: 9
A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey European Journal of Breast Health 19 (3), 235-252 , 2023 2023 Citations: 7
In silico identification of putative roles of food-derived xeno-mirs on diet-associated cancer D Pirim, B Dogan Nutrition and cancer 72 (3), 481-488 , 2020 2020 Citations: 7
Candidate biomarkers associated with circulating tumor cell status in metastatic colorectal cancer B Doğan, D Pirim, Ö Işık, T Evrensel Journal of clinical laboratory analysis 39 (7), e70013 , 2025 2025 Citations: 4
Different perspectives on translational genomics in personalized medicine B Doğan, HG Çelik, RD Küçükkaya, EG Acar, T Günel Journal of the Turkish German Gynecological Association 23 (4), 314 , 2022 2022 Citations: 4
The Potential Role of Egg‐Derived Xeno‐miRs in Chemotherapy Response: An In Silico Approach B Doğan Food Science & Nutrition 13 (6), e70332 , 2025 2025 Citations: 1
Selection of biomarker from candidate miRNAs for early detection of ovarian cancer B Doğan, T Günel, E Gümüşoğlu, M Hosseini, N Çevik, T Şenol, S Topuz, ... 2018 Citations: 1
The evaluation of the HSP70 and TCP1 status of circulating tumor cells derived from metastatic colorectal cancer patients D Pirim, B Dogan, FA Bağcı, Ö Işık, T Evrensel Journal of Experimental and Clinical Medicine 42 (4), 417-422 , 2025 2025
Integrative Bioinformatic Approach for microRNA Interactome Networks in Human Papillomavirus-16 Infection B Doğan The Eurasian Journal of Medicine 57 (3), e25817 , 2025 2025
The Development of a Fuzzy Logic System Using MATLAB for Early Detection of Hereditary Cancer in BRCA1/2 Negative Cases N Senturk, GP Volkan, SMB Ali, B Dogan, L Aliyeva, OS Sag, GS Temel, ... Balkan Journal of Medical Genetics 28 (1) , 2025 2025
Metastatik kolorektal kanserde dolaşımdaki tümör hücresi durumuyla ilişkili aday biyobelirteçlerin araştırılması B Doğan Bursa Uludağ Üniversitesi , 2024 2024
The Expression Analysis of Specific Genes in Ovarian Cancer E Gümüşoğlu-acar, B Doğan, MU Bilir, T Senturk-kirmizitas, S Topuz, ... Doğu Karadeniz Sağlık Bilimleri Dergisi 2 (Kongre Özel Sayısı), 136-143 , 2023 2023
Investigation of putative roles of smoking-associated salivary microbiome alterations on carcinogenesis by integrative in silico analysis B Doğan, B Ayar, D Pirim Computational Biology and Chemistry 102, 107805 , 2023 2023
